LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on Latin America, announced on July 31, 2026, that it has entered into an agreement with the Venezuelan Institute for Scientific Research (IVIC) to develop a digital platform module designed to facilitate access to laboratory and scientific services. The collaboration, conducted through LataMed AI’s Venezuelan subsidiary LATAMEDAI VE, aims to create a centralized digital interface for authorized business and institutional users.
Under the agreement, the two entities will work together on the design, development, testing, and implementation of a platform that would allow users to request available laboratory services, schedule appointments, track the status of submitted requests, access approved reports and documentation, and complete authorized payment processes. The proposed module is intended to serve organizations in sectors such as healthcare, pharmaceuticals, food production, and agriculture, though the specific services will be determined by IVIC and aligned with technical, operational, security, and legal requirements.
This initiative marks a significant step for LataMed AI, which has primarily focused on patient-facing telemedicine solutions. Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, “This agreement represents an opportunity to apply our technology to an important area of scientific and enterprise service delivery. Our objective is to work with IVIC to develop a responsible digital framework that makes it easier for authorized users to request services, manage appointments, monitor processes, and access approved information through a centralized platform.”
The platform’s planned features include electronic service requests, appointment scheduling, request-status tracking, secure payment facilitation, and controlled access to laboratory reports. The companies will begin by defining functional requirements, user-access procedures, data architecture, payment workflows, document-management capabilities, and a phased testing and implementation process. They will also establish protocols for handling, transmitting, storing, and authorizing access to laboratory information.
Management believes this project could expand LataMed AI’s capabilities beyond direct patient care, demonstrating how its technology can support institutional and enterprise workflows involving healthcare, scientific services, laboratory coordination, and digital documentation. The initiative aligns with the company’s broader strategy of building digital infrastructure that connects patients, healthcare professionals, pharmacies, insurers, payment providers, wellness organizations, and other ecosystem participants.
If successful, the module could potentially be adapted for other institutional and enterprise service environments in Venezuela and across Latin America. However, any future expansion would depend on separate agreements, technical readiness, regulatory approvals, and the needs of participating institutions. The agreement establishes a framework for development and evaluation but does not guarantee a specific implementation date, adoption level, revenue, or profitability.
LataMed AI is also developing AI-supported platforms for cardiovascular, pulmonary, and neurological health, though these remain in development and subject to regulatory requirements. For more information, visit https://latamed.ai or review the company’s SEC filings at https://www.sec.gov.
The announcement underscores the growing trend of digital transformation in Latin American healthcare and scientific services. By partnering with a prestigious research institution like IVIC, LataMed AI is positioning itself to play a key role in modernizing how laboratory services are accessed and managed, potentially improving efficiency and transparency for businesses and institutions in the region.
